Santhera Pharmaceuticals Holding AG (SANN.SW)
CHF 9.86
(2.49%)
CHF 9.86
(2.49%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.3 Million CHF | -112.32% |
| 2022 | 43.08 Million CHF | 97.92% |
| 2021 | 21.76 Million CHF | -62.95% |
| 2020 | 58.75 Million CHF | 105.18% |
| 2019 | 28.63 Million CHF | -12.15% |
| 2018 | 32.59 Million CHF | 311.8% |
| 2017 | 7.91 Million CHF | 115.89% |
| 2016 | -49.81 Million CHF | 35.19% |
| 2015 | -76.85 Million CHF | -340.83% |
| 2014 | -17.43 Million CHF | -245.66% |
| 2013 | -5.04 Million CHF | 49.94% |
| 2012 | -10.07 Million CHF | 52.39% |
| 2011 | -21.16 Million CHF | 48.89% |
| 2010 | -41.4 Million CHF | 22.34% |
| 2009 | -53.32 Million CHF | 28.91% |
| 2008 | -75 Million CHF | 29.65% |
| 2007 | -106.61 Million CHF | 14.19% |
| 2006 | -124.24 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 7.17 Million CHF | 235.15% |
| 2024 Q2 | 7.17 Million CHF | 37.73% |
| 2023 Q4 | -5.3 Million CHF | 43.48% |
| 2023 FY | -5.3 Million CHF | -112.32% |
| 2023 Q1 | 39.21 Million CHF | -8.98% |
| 2023 Q3 | -9.39 Million CHF | -123.58% |
| 2023 Q2 | 39.83 Million CHF | 1.58% |
| 2022 Q3 | 42.46 Million CHF | 51.95% |
| 2022 FY | 43.08 Million CHF | 97.92% |
| 2022 Q4 | 43.08 Million CHF | 1.47% |
| 2022 Q1 | 27.27 Million CHF | 25.28% |
| 2022 Q2 | 27.94 Million CHF | 2.46% |
| 2021 Q2 | 35.37 Million CHF | 2.16% |
| 2021 FY | 21.76 Million CHF | -62.95% |
| 2021 Q4 | 21.76 Million CHF | 2.88% |
| 2021 Q3 | 21.15 Million CHF | -40.19% |
| 2021 Q1 | 34.62 Million CHF | -41.07% |
| 2020 Q2 | 42.28 Million CHF | 2.52% |
| 2020 Q1 | 41.25 Million CHF | 44.05% |
| 2020 FY | 58.75 Million CHF | 105.18% |
| 2020 Q4 | 58.75 Million CHF | 1.33% |
| 2020 Q3 | 57.98 Million CHF | 37.12% |
| 2019 Q2 | 51.35 Million CHF | 2.02% |
| 2019 Q3 | 27.62 Million CHF | -46.22% |
| 2019 FY | 28.63 Million CHF | -12.15% |
| 2019 Q4 | 28.63 Million CHF | 3.67% |
| 2019 Q1 | 50.34 Million CHF | 54.43% |
| 2018 Q2 | 31.74 Million CHF | 0.0% |
| 2018 Q1 | 31.74 Million CHF | 301.0% |
| 2018 Q4 | 32.59 Million CHF | -5.62% |
| 2018 Q3 | 34.53 Million CHF | 8.81% |
| 2018 FY | 32.59 Million CHF | 311.8% |
| 2017 Q2 | -19.56 Million CHF | 0.0% |
| 2017 Q1 | -19.56 Million CHF | 60.73% |
| 2017 Q4 | 7.91 Million CHF | 0.0% |
| 2017 FY | 7.91 Million CHF | 115.89% |
| 2016 Q1 | -63.56 Million CHF | 17.3% |
| 2016 Q3 | -49.81 Million CHF | 21.63% |
| 2016 Q4 | -49.81 Million CHF | 0.0% |
| 2016 Q2 | -63.56 Million CHF | 0.0% |
| 2016 FY | -49.81 Million CHF | 35.19% |
| 2015 FY | -76.85 Million CHF | -340.83% |
| 2015 Q1 | -10.47 Million CHF | 39.91% |
| 2015 Q2 | -10.47 Million CHF | 0.0% |
| 2015 Q3 | -76.85 Million CHF | -633.67% |
| 2015 Q4 | -76.85 Million CHF | 0.0% |
| 2014 Q3 | -17.43 Million CHF | -245.93% |
| 2014 Q1 | -5.04 Million CHF | 0.08% |
| 2014 FY | -17.43 Million CHF | -245.66% |
| 2014 Q4 | -17.43 Million CHF | 0.0% |
| 2014 Q2 | -5.04 Million CHF | 0.0% |
| 2013 Q4 | -5.04 Million CHF | 0.0% |
| 2013 Q3 | -5.04 Million CHF | 33.39% |
| 2013 Q2 | -7.57 Million CHF | 0.0% |
| 2013 Q1 | -7.57 Million CHF | 24.85% |
| 2013 FY | -5.04 Million CHF | 49.94% |
| 2012 Q2 | -14 Million CHF | 0.0% |
| 2012 Q3 | -12.28 Million CHF | 12.28% |
| 2012 Q4 | -10.07 Million CHF | 17.97% |
| 2012 FY | -10.07 Million CHF | 52.39% |
| 2011 Q4 | -21.16 Million CHF | 0.0% |
| 2011 FY | -21.16 Million CHF | 48.89% |
| 2011 Q2 | -29.14 Million CHF | 0.0% |
| 2010 FY | -41.4 Million CHF | 22.34% |
| 2010 Q2 | -37.18 Million CHF | 0.0% |
| 2010 Q4 | -41.4 Million CHF | 0.0% |
| 2009 FY | -53.32 Million CHF | 28.91% |
| 2009 Q4 | -53.32 Million CHF | 0.0% |
| 2008 FY | -75 Million CHF | 29.65% |
| 2007 FY | -106.61 Million CHF | 14.19% |
| 2006 FY | -124.24 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Addex Therapeutics Ltd | -3.52 Million CHF | -50.746% |
| BB Biotech AG | 304.39 Million CHF | 101.744% |
| Basilea Pharmaceutica AG | 116.11 Million CHF | 104.571% |
| Evolva Holding SA | -5.83 Million CHF | 9.089% |
| Idorsia Ltd | 1.05 Billion CHF | 100.501% |
| Kuros Biosciences AG | -8.69 Million CHF | 38.918% |
| Molecular Partners AG | -183.23 Million CHF | 97.103% |
| Relief Therapeutics Holding AG | -10.24 Million CHF | 48.189% |